Oncology Med Enters Into Letter of Intent to Acquire Medical/Radiation Company Which Has Gross Revenues of $2,800,000.00
30 Januar 2008 - 1:00PM
Marketwired
PITTSBURGH, PA a Pittsburgh based cancer treatment solutions
group, announced today that it has entered into a letter of intent
to acquire a synergistic company in the field of physics and
radiation that has annual revenues of $2,800,000.00, operates on a
national scale, and is profitable. Upon the closing of this
acquisition, which is subject to due diligence review by both
parties and the execution of definitive agreements of purchase, the
combined entity will have an annual revenue run rate of
$5,000,000.00. The Company is prevented from announcing the name of
the acquisition candidate until the completion of the due diligence
period and execution of a definitive agreement of purchase.
According to William Walker, Ph.D., Oncology Med's CEO and
founder, "We are extremely excited about the agreement we have
entered into to acquire this company and intend to move diligently
and expediently toward a closing which we expect to occur on or
about May 2008. The company is a leader in their field and presents
many cross marketing opportunities for us. The management has a
pristine reputation and credentials and will be a great addition to
the Oncology Med team. I believe this will be one of many
acquisitions that we will pursue. As always our plan is to take
advantage of our organic growth in addition to exciting and
accretive acquisitions."
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of
services related to the treatment of various cancers. It currently
provides analysis and design of radiation treatment plans in order
for radiation oncologists to administer radiation treatments to
cancer patients. Current services facilitate radiation treatment
programs ranging from external beam radiation to more advanced
radiation treatment technologies.
More information about Oncology Med, Inc. can be found at
www.oncologymed.com.
NOTE: This press release may contain "forward-looking
statements." In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue" or the negative of
such terms and other comparable terminology. These forward-looking
statements include, without limitation, statements about our market
opportunity, our strategies, competition, expected activities and
expenditures as we pursue our business plan, and the adequacy of
our available cash resources. Although we believe that the
expectations reflected in any forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Actual results may differ materially
from the predictions discussed in these forward-looking statements.
Changes in the circumstances upon which we base our predictions
and/or forward-looking statements could materially affect our
actual results.
For information, please contact us at Email Contact
Bellatora (PK) (USOTC:ECGR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bellatora (PK) (USOTC:ECGR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
